PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer

References

• Askoxylakis V, Marr A, Altmann A, et al. (2013). Peptide-based targeting of the platelet-derived growth factor receptor beta. Mol Imaging Biol 15:212–21.
   PubMed Web of Science ®Google Scholar
• Azzouzi A-R, Vincendeau S, Barret E, et al. (2017). Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol 18:181–91.
   PubMed Web of Science ®Google Scholar
• Baluk P, Hashizume H, McDonald DM. (2005). Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15:102–11.
   PubMed Web of Science ®Google Scholar
• Bugaj AM. (2011). Targeted photodynamic therapy-a promising strategy of tumor treatment. Photochem Photobiol Sci 10:1097–109.
   PubMed Web of Science ®Google Scholar
• Chang WG, Andrejecsk JW, Kluger MS, et al. (2013). Pericytes modulate endothelial sprouting. Cardiovasc Res 100:492–500.
   PubMed Web of Science ®Google Scholar
• Dąbrowski JM. (2017). Reactive oxygen species in photodynamic therapy: mechanisms of their generation and potentiation. Adv Inorgan Chem 70:343–94.
   Web of Science ®Google Scholar
• Dabrowski JM, Arnaut LG. (2015). Photodynamic therapy (PDT) of cancer: from local to systemic treatment. Photochem Photobiol Sci 14:1765–80.
   PubMed Web of Science ®Google Scholar
• Dolmans DEJGJ, Dai F, Jain RK. (2003). Photodynamic therapy for cancer. Nat Rev Cancer 3:380–5.
   PubMed Web of Science ®Google Scholar
• Fingar VH, Kik PK, Haydon PS, et al. (1999). Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer 79:1702–8.
   PubMed Web of Science ®Google Scholar
• Geevarghese A, Herman IM. (2014). Pericyte-endothelial crosstalk: implications and opportunities for advanced cellular therapies. Transl Res 163:296–306.
   PubMed Web of Science ®Google Scholar
• Gollmer A, Arnbjerg J, Blaikie FH, et al. (2011). Singlet oxygen sensor green(R): photochemical behavior in solution and in a mammalian cell. Photochem Photobiol 87:671–9.
   Google Scholar
• Heukers R, van Bergen en Henegouwen PM, Oliveira S. (2014). Nanobody-photosensitizer conjugates for targeted photodynamic therapy. Nanomedicine 10:1441–51.
   PubMed Web of Science ®Google Scholar
• Hofstrom C, Orlova A, Altai M, et al. (2011). Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I. J Med Chem 54:3817–26.
   PubMed Web of Science ®Google Scholar
• Holland PM. (2013). Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL. Cancer Lett 332:156–62.
   PubMed Web of Science ®Google Scholar
• Kamarulzaman EE, Benachour H, Barberi-Heyob M, et al. (2011) Vascular targeted photodynamic therapy (VTP). In: Gali-Muhtasib H, ed. Advances in cancer therapy. Croatia: InTech, 99–122.
   Google Scholar
• Kim D, Yan Y, Valencia CA, Liu R. (2012). Heptameric targeting ligands against EGFR and HER2 with high stability and avidity. PLoS One 7:e43077.
   PubMed Web of Science ®Google Scholar
• Krzykawska-Serda M, Dabrowski JM, Arnaut LG, et al. (2014). The role of strong hypoxia in tumors after treatment in the outcome of bacteriochlorin-based photodynamic therapy. Free Radic Biol Med 73:239–51.
   PubMed Web of Science ®Google Scholar
• Li R, Yang H, Jia D, et al. (2016). Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. J Control Release 228:96–106.
   PubMed Web of Science ®Google Scholar
• Lindborg M, Cortez E, Hoiden-Guthenberg I, et al. (2011). Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor beta in vivo. J Mol Biol 407:298–315.
   PubMed Web of Science ®Google Scholar
• Lowa SW, Lin AW. (2000). Apoptosis in cancer. Carcinogenesis 21:489–95.
   Web of Science ®Google Scholar
• Marr A, Nissen F, Maisch D, et al. (2013). Peptide arrays for development of PDGFRβ Affine molecules. Mol Imaging Biol 15:391–400.
   PubMed Web of Science ®Google Scholar
• McGurn LD, Moazami-Goudarzi M, White SA, et al. (2016). The structure, kinetics and interactions of the β-carboxysomal β-carbonic anhydrase, CcaA. Biochem J 473:4559–72.
   PubMed Web of Science ®Google Scholar
• Mitsunaga M, Ogawa M, Kosaka N, et al. (2011). Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 17:1685–91.
   PubMed Web of Science ®Google Scholar
• Paulsson J, Sjoblom T, Micke P, et al. (2009). Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175:334–41.
   PubMed Web of Science ®Google Scholar
• Prakash J, de Jong E, Post E, et al. (2010). A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier. J Control Release 145:91–101.
   PubMed Web of Science ®Google Scholar
• Schmitt F, Juillerat-Jeanneret L. (2012). Drug targeting strategies for photodynamic therapy. Anticancer Agents Med Chem 12:500–25.
   PubMed Web of Science ®Google Scholar
• Setsukinai K, Urano Y, Kakinuma K, et al. (2003). Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem 278:3170–5.
   PubMed Web of Science ®Google Scholar
• Sexton K, Tichauer K, Samkoe KS, et al. (2013). Fluorescent affibody peptide penetration in glioma margin is superior to full antibody. PLoS One 8:e60390,
   PubMed Web of Science ®Google Scholar
• Shafirstein G, Bellnier D, Oakley E, et al. (2017). Interstitial photodynamic therapy – a focused review. Cancers 9:e12.
   PubMed Web of Science ®Google Scholar
• Shirasu N, Nam SO, Kuroki M. (2013). Tumor-targeted photodynamic therapy. Anticancer Res 33:2823–32.
   PubMed Web of Science ®Google Scholar
• Shirasu N, Yamada H, Shibaguchi H, et al. (2014). Potent and specific antitumor effect of CEA-targeted photoimmunotherapy. Int J Cancer 135:2697–710.
   PubMed Web of Science ®Google Scholar
• Srivatsan A, Ethirajan M, Pandey SK, et al. (2011). Conjugation of cRGD peptide to chlorophyll a based photosensitizer (HPPH) alters its pharmacokinetics with enhanced tumor-imaging and photosensitizing (PDT) efficacy. Mol Pharm 8:1186–97.
   PubMed Web of Science ®Google Scholar
• Tao Z, Yang H, Shi Q, et al. (2017). Targeted delivery to tumor-associated pericytes via an affibody with high affinity for PDGFRβ enhances the in vivo antitumor effects of human TRAIL. Theranostics 7:2261–76.
   PubMed Web of Science ®Google Scholar
• Thomas N, Pernot M, Vanderesse R, et al. (2010). Photodynamic therapy targeting neuropilin-1: interest of pseudopeptides with improved stability properties. Biochem Pharmacol 80:226–35.
   PubMed Web of Science ®Google Scholar
• Tolmachev V, Varasteh Z, Honarvar H, et al. (2014). Imaging of platelet-derived growth factor receptor beta expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591. J Nucl Med 55:294–300.
   PubMed Web of Science ®Google Scholar
• van Driel PB, Boonstra MC, Slooter MD, et al. (2016). EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. J Control Release 229:93–105.
   PubMed Web of Science ®Google Scholar
• van Straten D, Mashayekhi V, de Bruijn HS, et al. (2017). Oncologic photodynamic therapy: basic principles, current clinical status and future directions. Cancers 9:e19.
   PubMed Web of Science ®Google Scholar
• Wei D, Fan Q, Cai H, et al. (2015). CF750-A33scFv-Fc-based optical imaging of subcutaneous and orthotopic xenografts of GPA33-positive colorectal cancer in mice. BioMed Res Int 2015:505183.
   PubMed Web of Science ®Google Scholar